Skip to search formSkip to main contentSkip to account menu

0.05 ML ranibizumab 6 MG/ML Injection [Lucentis]

Known as: LUCENTIS 0.3 MG in 0.05 ML Injection, Lucentis 0.3 MG per 0.05 ML Injection, RANIBIZUMAB 6 mg in 1 mL INTRAVITREAL INJECTION, SOLUTION [LUCENTIS] 
National Institutes of Health

Related topics

Related topics

9 relations
HistidineInjectionLucentisPolysorbate 20

Broader (1)

ranibizumab Injection [Lucentis]

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Safety and tolerability evaluation after repeated intravitreal injections of a humanized anti-VEGF-A monoclonal antibody (PRO-169) versus ranibizumab in New Zealand white rabbits
Background To evaluate the retinal toxicity after repeated intravitreal injections of a humanized anti-VEGF-A monoclonal antibody… 
2019
2019
Ultrastruktureller und klinischer Vergleich des Ergebnisses bei PDR-Patienten, behandelt mit Ranibizumab oder Aflibercept – von Grundlagenforschungen zu den klinischen Therapien
Zusammenfassung Hintergrund Die proliferative diabetische Retinopathie (PDR) ist eine der häufigsten Erblindungsursachen weltweit… 
2017
2017
Cytosolic expression of functional Fab fragments in Escherichia coli using a novel combination of dual SUMO expression cassette and EnBase® cultivation mode
The Escherichia coli expression system is highly effective in producing recombinant proteins. However, there are some limitations… 
2015
2015
Vergleich von intravitrealem Dexamethason-Implantat mit intravitrealem Ranibizumab als Erstbehandlung des Makulaödems bei retinalen venösen Gefäßverschlüssen
Zusammenfassung Hintergrund: Die vorliegende Arbeit untersucht den Vergleich der intravitrealen Therapie mit Dexamethason… 
2013
2013
The Effect of Glutathione as Chain Transfer Agent in PNIPAAm-Based Thermo-responsive Hydrogels for Controlled Release of Proteins
To control degradation and protein release using thermo-responsive hydrogels for localized delivery of anti-angiogenic proteins… 
2013
2013
[The treatment of age-related macular degeneration (AMD) in practice].
AIM The purpose of this paper is to describe and analyze the diagnosis and treatment of age-related macular degeneration (AMD… 
2012
2012
Regression of rubeosis in the fellow eye after intravitreal ranibizumab injection
The growth of abnormal vessels on the iris called rubeosis is induced by vascular endothelial growth factor (VEGF). The… 
2011
2011
Does Ranibizumab (Lucentis®) Change Retrobulbar Blood Flow in Patients with Neovascular Age-Related Macular Degeneration?
Purpose: To investigate the effects of intravitreal ranibizumab on retrobulbar blood flow in patients with neovascular age… 
2010
2010
Volumenberechnungen zur aktuellen intravitrealen Injektion von Lucentis®
ZusammenfassungHintergrundMedikamente zur Blockade des „vascular endothelial growth factor“ (VEGF) werden aktuell zur Therapie… 
2005
2005
Anti-Angiogenese bei neovaskulärer Makuladegeneration: Neue therapeutische Strategien
ZusammenfassungHintergrundDie Behandlungsmöglichkeiten bei der neovaskulären altersbezogenen Makuladegeneration (AMD) haben sich… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)